In the present study, we provided the first experimental evidence that BM-MSCs attenuate cisplatin-induced renal injury and fibrosis by the regulation of miR-146a-5p and the targeting gene Tfdp2, indicating that BM-MSCs may be a promising approach for developing novel therapeutics to treat renal fibrosis. The gene discussed is TFDP2; the disease is renal fibrosis.